MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00365989
Recruitment Status : Completed
First Posted : August 18, 2006
Last Update Posted : March 29, 2018
Information provided by (Responsible Party):

Brief Summary:
This is a phase 3 study to determine the safety of the new features to the FDA approved ExAblate device using a new method to ablate fibroids deemed Enhanced Sonication.

Condition or disease Intervention/treatment Phase
Uterine Leiomyoma Uterine Fibroids Device: ExAblate 2000 Not Applicable

Detailed Description:
Uterine leiomyoma (fibroids) are the most common neoplasms of the female pelvis. These benign tumors are generally oval in shape, and often highly vascular. On T2 weighted MR imaging exams, or T1 exams with contrast, uterine fibroids are easily identifiable. They occur in 20-25% of women of reproductive age and can cause a variety of problems generally described as either bleeding or mass effects from the fibroid. InSightec has developed an Enhanced Sonication (ES) technique for the ablation of these fibroids. This mode of tissue ablation has been added to the already FDA approved ExAblate system. The goal of this ES technique is to provide an additional treatment tool that will enhance the treatment effect without additional risks while preserving ALL clinical features of the current commercially approved version.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Clinical Study To Evaluate the Safety and Efficacy of MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication Techniques
Study Start Date : October 2006
Actual Primary Completion Date : August 2008
Actual Study Completion Date : August 2008

Arm Intervention/treatment
Experimental: 1 Device: ExAblate 2000

Primary Outcome Measures :
  1. The primary end point is to determine the safety of the new Enhanced Sonication technique and assure no new safety issues are introduced. [ Time Frame: Within 1 month of treatment ]

Secondary Outcome Measures :
  1. The secondary end point of the study is to evaluate the ratio of normalized Enhanced Sonication thermal dose volume Vs. that of 'nominal' sonication. [ Time Frame: Within 1 month of treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Women age 18 or older, who present with symptomatic fibroids
  2. Women who have given written informed consent
  3. Women who are able and willing to attend all study visits.
  4. Patient is pre or peri-menopausal (within 12 months of last menstrual period).
  5. Able to communicate sensations during the ExAblate procedure.
  6. Uterine fibroids, which are device accessible (i.e., positioned in the uterus such that they can be accessed without being shielded by bowel or bone).
  7. Fibroids(s) clearly visible on non-contrast MRI.

Exclusion Criteria:

  1. Women who are pregnant, as confirmed by serum test at time of screening, or urine pregnancy test on the day of treatment
  2. Patient who desire to become pregnant in the future.
  3. Patients who are breast-feeding.
  4. Patients with an active pelvic inflammatory disease (PID)
  5. Active local or systemic infection
  6. Metallic implants that are incompatible with MRI
  7. Known intolerance to the MRI contrast agent (e.g. Gadolinium or Magnevist)
  8. Severe claustrophobia that would prevent completion of procedure in the MR unit.
  9. Extensive abdominal scarring in the beam pass or dermoid cyst of the ovary anywhere in the treatment path.
  10. Known or suspected pelvic carcinoma or pre-malignant conditions, including sarcoma and adenomatous hyperplasia.
  11. Pedunculated fibroids.
  12. Intrauterine device (IUD) anywhere in the treatment path
  13. Undiagnosed vaginal bleeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00365989

United States, California
University of California at San Diego
La Jolla, California, United States, 92037
United States, Massachusetts
Lahey Clinic
Burlington, Massachusetts, United States, 01805
United States, Michigan
Kalamazoo, Michigan, United States, 49048
United States, New York
Cornell Vascular
New York, New York, United States, 10022
Canada, Ontario
Toronto General Hospital
Toronto, Ontario, Canada, MG5 2C4
Sponsors and Collaborators
Principal Investigator: Anne Roberts, M.D. University of California, San Diego
Principal Investigator: Mark Shaman, M.D. KNI
Principal Investigator: Robert Min, M.D. Cornell
Principal Investigator: David Gianfelice, M.D. Toronto General Hospital
Principal Investigator: George Holland, M.D. Lahey Clinic

Additional Information:
Responsible Party: InSightec Identifier: NCT00365989     History of Changes
Other Study ID Numbers: UF018
First Posted: August 18, 2006    Key Record Dates
Last Update Posted: March 29, 2018
Last Verified: March 2018

Keywords provided by InSightec:
benign tumors

Additional relevant MeSH terms:
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Connective Tissue Diseases